When the FOURIER trial was published in 2017, cardiologists and lipidologists everywhere hailed it as proof that lowering LDL with PCSK9 inhibitors “saves lives.” But when you actually read the data, not the press releases, it’s hard not to shake your head. Over a median of 2.2 years, evolocumab (Repatha) reduced nonfatal heart attacks by
The high cost of PCSK9 inhibitors like Repatha originally appeared in KevinMD.com.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.